- Pressemitteilung BoxID 150892
Radianskin - combining efficacy and skin tolerance for advanced skin whitening
The skin whitening segment is still one of the most dynamic in the cosmetics and care market. However, this does not mean that success can be taken for granted, or that formulating these products does not pose a unique set of challenges. Consumers of whitening products are looking for great lightening results without cell damage or any other adverse side-effects. On the other hand, there is growing interest in anti-aging skin care products that aim to improve skin radiance, and this trend is broadening the market for whitening ingredients. The combination of all these factors has boosted demand for new whiteners with the right combination of performance attributes.
In response, LS has now launched Radianskin, a new skin whitener that perfectly fulfills all the characteristics required in a "modern" skin lightener. The active ingredient in Radianskin is a pure single molecule, rather than a less well defined extract, and provides a significant and visible lightening effect. Based on a scientific approach, Radianskin employs an alternate mode of action when compared to commonly used tyrosinase inhibitors, which differentiates it from most of the existing products on the market. In addition, Radianskin offers a good photoprotective effect helping to prevent skin against UV induced damages while ensuring high skin tolerance due to its positive safety profile.
Scientifically proven effects
Clinical studies performed on Asian volunteers have shown that 1% Radianskin significantly lightens the skin after as little as 28 days of treatment, with a lightening effect comparable to market benchmarks. Other in vitro efficacy studies have also proven the active's photoprotective effect against UVB-induced damage, its good skin penetration, and its superior inhibition of melanogenesis compared to well-known skin lightening products, without any cytotoxic effects.
Radianskin is compatible with a wide range of other ingredients such as aluminum salts, AHAs, vitamin C, sun filters, and TiO2. This makes formulating and handling products that contain this active straightforward, thus providing significant advantages for formulators and manufacturers. Further benefits include excellent stability, and the fact that it does not affect the color or odor of final formulations. Says Anne-Laurie Rodrigues, LS's Communications Manager: "Radianskin offers a unique combination of efficacy, skin tolerance and ease of use. It is suitable for a wide range of skincare applications, such as skin whitening and anti-aging products, including those for sensitive skin. The skin whitening market is already growing rapidly, but we believe that this product can give it further stimulus towards developing innovative line extensions within the men's care and body care categories."
- Whitening ranges
- Lightening care products
- Anti-aging skin care products to improve skin radiance
- Anti-age spot creams and serums
- Men's care products
- Whitening body care (hands, armpits, chest and forearms)
About Laboratoires Sérobiologiques
Laboratoires Sérobiologiques is Cognis Care Chemicals' active ingredients business. It specializes in the development, manufacture and marketing of innovative cosmetic concepts and active ingredients.
BASF Personal Care and Nutrition GmbH
Cognis is a worldwide supplier of innovative specialty chemicals and nutritional ingredients, with a particular focus on the areas of wellness and sustainability. The company employs about 5,600 people, and it operates production sites and service centers in 30 countries. Cognis has dedicated its activities to a high level of sustainability and delivers natural source raw materials and ingredients for food, nutrition and healthcare markets, and the cosmetics, detergents and cleaners industries. Another main focus is on products for a number of other industries, such as coatings and inks, lubricants, as well as agriculture and mining.
Cognis is owned by private equity funds advised by Permira, GS Capital Partners, and SV Life Sciences. In 2008, Cognis recorded sales of about 3 billion euros and an Adjusted EBITDA (operating result) of 351 million euros.
Diese Pressemitteilungen könnten Sie auch interessieren
Beim Deutschen Evangelischen Kirchentag ist auf dem Berliner Messegelände in der Medienmeile in Halle 3.2, Stand F 16, auch die Medienagentur...
Die Ordination von Frauen zum Dienst als Pfarrerinnen war Thema eines Podiums auf dem Deutschen Evangelischen Kirchentag, der vom 24. bis 28....